These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1142 related items for PubMed ID: 11353048

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Molecular genetic analysis of surveillance biopsy samples from Barrett's mucosa--significance of sampling.
    Werther M, Saure C, Pahl R, Schorr F, Rüschoff J, Alles JU, Heinmöller E.
    Pathol Res Pract; 2008; 204(5):285-94. PubMed ID: 18337019
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Accumulation of p53 protein in normal, dysplastic, and neoplastic Barrett's oesophagus.
    Krishnadath KK, Tilanus HW, van Blankenstein M, Bosman FT, Mulder AH.
    J Pathol; 1995 Feb; 175(2):175-80. PubMed ID: 7738712
    [Abstract] [Full Text] [Related]

  • 8. Diagnostic significance of nuclear p53 expression in the surveillance of Barrett's esophagus--a longitudinal study.
    Klump B, Hsieh CJ, Holzmann K, Borchard F, Gaco V, Greschniok A, Eckardt VF, Bettendorf U, Gregor M, Porschen R.
    Z Gastroenterol; 1999 Oct; 37(10):1005-11. PubMed ID: 10549095
    [Abstract] [Full Text] [Related]

  • 9. Aneuploidy and overexpression of Ki67 and p53 as markers for neoplastic progression in Barrett's esophagus: a case-control study.
    Sikkema M, Kerkhof M, Steyerberg EW, Kusters JG, van Strien PM, Looman CW, van Dekken H, Siersema PD, Kuipers EJ.
    Am J Gastroenterol; 2009 Nov; 104(11):2673-80. PubMed ID: 19638963
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. p53-mutant clones and field effects in Barrett's esophagus.
    Prevo LJ, Sanchez CA, Galipeau PC, Reid BJ.
    Cancer Res; 1999 Oct 01; 59(19):4784-7. PubMed ID: 10519384
    [Abstract] [Full Text] [Related]

  • 13. p53 immunoreactivity in Barrett's metaplasia, dysplasia, and adenocarcinoma--a case report.
    Kimura H, Konishi K, Kaji M, Maeda K, Yabushita K, Miwa A.
    Hepatogastroenterology; 2001 Oct 01; 48(42):1662-4. PubMed ID: 11813596
    [Abstract] [Full Text] [Related]

  • 14. K-ras point mutations are rare events in premalignant forms of Barrett's oesophagus.
    Trautmann B, Wittekind C, Strobel D, Meixner H, Keymling J, Gossner L, Ell C, Hahn EG.
    Eur J Gastroenterol Hepatol; 1996 Aug 01; 8(8):799-804. PubMed ID: 8864678
    [Abstract] [Full Text] [Related]

  • 15. Molecular evaluation of ablative therapy of Barrett's oesophagus.
    Hage M, Siersema PD, Vissers KJ, Steyerberg EW, Haringsma J, Kuipers EJ, van Dekken H.
    J Pathol; 2005 Jan 01; 205(1):57-64. PubMed ID: 15586364
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. [Overexpression of protein p53 and Barrett esophagus. A frequent and early event in the course of carcinogenesis].
    Fléjou JF, Volant A, Diebold MD, Sagan C, Vissuzaine C, Croué A, Robaszkiewicz M, Potet F.
    Gastroenterol Clin Biol; 1995 May 01; 19(5):475-81. PubMed ID: 7589998
    [Abstract] [Full Text] [Related]

  • 20. Survivin, a potential biomarker in the development of Barrett's adenocarcinoma.
    Vallböhmer D, Peters JH, Oh D, Kuramochi H, Shimizu D, Demeester SR, Hagen JA, Chandrasoma PT, Danenberg KD, DeMeester TR, Danenberg P.
    Surgery; 2005 Oct 01; 138(4):701-6; discussion 706-7. PubMed ID: 16269299
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 58.